<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000684.v1.p1" parentStudy="phs000684.v1.p1" createDate="2013-11-21" modDate="2014-05-05">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>Anand Swaroop, PhD</td><td>National Eye Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Gon&#231;alo Abecasis, PhD</td><td>University of Michigan, Ann Arbor, MI, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Dwight Stambolian, MD, PhD</td><td>University of Pennsylvania, Philadelphia, PA, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Albert Edwards, MD, PhD</td><td>Mayo Clinic, Rochester, MN, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Richard K. Wilson, PhD</td><td>Washington University School of Medicine, St. Louis, MO, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Age related Macular Degeneration - MMAP Cohort: Association and Sequencing Studies</StudyNameEntrez>
	<StudyNameReportPage>Age related Macular Degeneration (AMD) - Michigan, Mayo, AREDS, Pennsylvania (MMAP) Cohort Study: Association and Sequencing Studies</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Age-related Macular Degeneration (AMD) is a leading cause of incurable blindness in people over the age of 65. AMD is a late-onset multi-factorial neurodegenerative disease and its pathogenesis involves interaction of genetic and environmental factors. Several chromosomal regions have been associated with AMD susceptibility through linkage analysis (<a href="http://www.ncbi.nlm.nih.gov/pubmed/19405847">Swaroop et al., 2009</a>). More recent studies provide strong evidence that variants within the CFH gene cluster on chromosome 1 and at/near LOC387715/ARMS2 on chromosome 10 are strongly associated with the disease. Variants at other genes including C2/BF, C3, CFI and APOE4, also contribute to AMD susceptibility.</p> <p>Our primary goals are to identify genetic variants and haplotypes that are associated with AMD. The underlying hypothesis is that DNA variation(s) in multiple genetic susceptibility loci will predispose individuals to AMD pathogenesis, and comparison of DNA of cases and controls should identify these susceptibility variants. Our studies are focused on the genetic analysis of advanced AMD and should provide novel insights into disease diagnosis, progression and pathology.</p> <p>We have assembled a collaborative group of researchers from the University of Michigan, Mayo Clinic, University of Pennsylvania, and the AREDS group including National Eye Institute intramural investigators, who collected clinical data and DNA from a large number of patients affected with AMD and from unaffected controls. The primary source of funding was National Eye Institute.</p> <p>Study 1: To identify genetic variants and haplotypes that are associated with AMD, we submitted and obtained usable genotyping data on 2185 patients and 1155 controls from the Center for Inherited Disease Research (CIDR).</p> <p>Study 2: To identify rare coding variants associated with a large increase in risk of AMD, 10 candidate loci spanning 57 genes were sequenced in 2,335 cases and 789 controls. Probes were designed to capture 96.5% of the coding sequence and 35% of total locus sequence, generating an average 123Mb of on-target sequence per individual at 127x average depth.</p> <p><b>Substudies:</b></p> <p><li><a href="./study.cgi?study_id=phs000182">phs000182</a> AMD-MMAP Cohort Study: A Joint Genome-Wide Asscociation Study</li></p> <p><li><a href="./study.cgi?study_id=phs000246">phs000246</a> Fuchs&#39; Corneal Dystrophy GWAS</li></p> <p><li><a href="./study.cgi?study_id=phs000457">phs000457</a> MMAP Methylation in AMD</li></p> <p><li><a href="./study.cgi?study_id=phs000685">phs000685</a> Age-Related Macular Degeneration Targeted Sequencing Study</li></p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Inclusion criteria:<br/> 1. Affected with geographic atrophy, neovascularization, or large drusen in at least one eye. If any of the above are only found in one eye, then the evidence of drusen, pigment changes must be found in the fellow eye.<br/> 2. Control patients have been examined and found to have no more than 5 hard drusen and are over the age of 50 (Mayo clinic cohort) or small drusen and pigment changes in one eye only and are over the age of 60 (UMich and UPenn clinic cohorts).<br/> </p> <p>Exclusion criteria:<br/> 1. Evidence or history of severe macular disease or vision loss before the age of 40, or diagnosis with symptoms consistent with a juvenile macular or retinal degeneration, or macular damage resulting from ocular trauma, retinal detachment, high myopia, chorioretinal infection, or inflammatory disease, or choroidal dystrophy or other retinal insult in which the fundus was not gradable. </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Zhan, X., Larson,D.E., Wang, D., Koboldt, D.C., et al." title="Targeted Sequencing, Augmented with Public Resources, Identifies a Rare Complement 3 Allele Associated with AMD" journal="Nature Genetics. Appeared online 15 Sep 2013"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20385819"/>
		</Publication>
		<Publication>
			<Pubmed pmid="14968411"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15111581"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15987700"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15761121"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15829498"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15895326"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16225921"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16936733"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17884985"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17911160"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18369057"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18385087"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19043567"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19169411"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19405847"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19469037"/>
		</Publication>
	</Publications>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>Anand Swaroop, PhD</AttName>
			<Institution>National Eye Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Gon&#231;alo Abecasis, PhD</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Dwight Stambolian, MD, PhD</AttName>
			<Institution>University of Pennsylvania, Philadelphia, PA, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Albert Edwards, MD, PhD</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Richard K. Wilson, PhD</AttName>
			<Institution>Washington University School of Medicine, St. Louis, MO, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Elaine Mardis, PhD</AttName>
			<Institution>Washington University School of Medicine, St. Louis, MO, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>John Heckenlively, MD</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Emily Chew, MD</AttName>
			<Institution>National Eye Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>William Brown, OD</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Keith Baratz, MD</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Coordinator">
			<AttName>Kari Branham, MS</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Biostatisticians">
			<AttName>Wei Chen, PhD</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Biostatisticians">
			<AttName>Euijung Ryu, PhD</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Biostatisticians">
			<AttName>Alice Henning, MS</AttName>
			<Institution>The EMMES Corporation, Rockville, MD, USA</Institution>
		</Header>
		<Header title="Research Technologist">
			<AttName>Mohammad Othman, PhD</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Research Technologist">
			<AttName>Nirubol Tosakulwong, BS</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Genotyping Center">
			<AttName>Center for Inherited Disease Research (CIDR)</AttName>
			<Institution>Johns Hopkins University, Baltimore, MD, USA</Institution>
		</Header>
		<Header title="Sequencing Center">
			<AttName>The Genome Institute</AttName>
			<Institution>Washington University School of Medicine, St. Louis, MO, USA</Institution>
		</Header>
		<Header title="Funding Source for Sequencing">
			<AttName>U54 HG003079</AttName>
			<Institution>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>The University of Michigan genetic study of AMD was started in 1998 by Dr. Anand Swaroop with the goal of identifying susceptibility loci for AMD. Affected patients were enrolled primarily from the retina clinic of the Kellogg Eye Center with the help of clinicians and staff. The control participants were enrolled primarily from the general ophthalmology clinics of the Kellogg Eye Center. After the enrollment of affected probands, we sought to enroll affected and unaffected family members. To date, more than 2300 affected and unaffected subjects have been enrolled in the study.</p> <p>The University of Michigan genetic studies of AMD have resulted in several peer-reviewed manuscripts, notably a whole-genome linkage scan for age-related macular degeneration (<a href="http://www.ncbi.nlm.nih.gov/pubmed/14968411">Abecasis et al., 2004</a>) and a joint-analysis of several linkage scans (<a href="http://www.ncbi.nlm.nih.gov/pubmed/15987700">Fisher et al., 2005</a>), a dissection of the roles of complement factor H (<a href="http://www.ncbi.nlm.nih.gov/pubmed/15895326">Zareparsi et al., 2005a</a>) and TLR4 (<a href="http://www.ncbi.nlm.nih.gov/pubmed/15829498">Zareparsi et al., 2005b</a>), and recent detailed analyses of the complement factor H locus (<a href="http://www.ncbi.nlm.nih.gov/pubmed/16936733">Li et al., 2006</a>) and LOC387715/ARMS2 locus (<a href="http://www.ncbi.nlm.nih.gov/pubmed/17884985">Kanda et al., 2007</a>) among others.</p> <p>For the University of Pennsylvania cohort, subjects were ascertained through the ophthalmology practices of the University of Pennsylvania (Dr. Dwight Stambolian and colleagues) as well as subjects who participated in the clinical trial of the CAPT study.</p> <p>The Mayo subjects were enrolled from the practices of Dr. Albert Edwards and selected colleagues from Dallas, TX and Rochester, MN starting in 1998. The subjects have been used in a number of studies and contributed to one of the initial reports of association between macular degeneration and the CFH locus (<a href="http://www.ncbi.nlm.nih.gov/pubmed/15761121">Edwards et al., 2005</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/18385087">2008</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/19469037">2009</a>; <a href="http://www.ncbi.nlm.nih.gov/pubmed/19169411">Park et al., 2009</a>).</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="0" shortName="NRUP" longName="Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects"/>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
		<ConsentGroup groupNum="2" shortName="DS-ED" longName="Disease-Specific (Eye Disease)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NEI</DacName>
      <DacFullName>National Eye Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000684.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000684.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000684.v1.p1" FileName="NEI-AMD_DUC_general.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.
Study participant consented to general research use. These participants submitted a genetic specimen and the genetic specimen data for these participants can be obtained by contacting the PI of the study or NEI DAC (Data Access Committee).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Disease-Specific (Eye Disease)</ConsentName>
        <ConsentAbbrev>DS-ED</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Eye Disease.
These participants submitted a genetic specimen and the genetic specimen data for these participants can be obtained by contacting the PI of the study or NEI DAC (Data Access Committee).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
